Suppr超能文献

一种新型小直径纳米纺织动脉移植物与手术可行性和安全性相关,并能增加猪的跨壁内皮细胞生长。

A novel small diameter nanotextile arterial graft is associated with surgical feasibility and safety and increased transmural endothelial ingrowth in pig.

机构信息

Bristol Heart Institute and Translational Biomedical Research Centre, Faculty of Health Science, University of Bristol, Bristol, BS2 8HW, UK.

Centre for Nanosciences & Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi, 682 041, India.

出版信息

J Nanobiotechnology. 2022 Feb 8;20(1):71. doi: 10.1186/s12951-022-01268-1.

Abstract

Globally, millions of patients are affected by myocardial infarction or lower limb gangrene/amputation due to atherosclerosis. Available surgical treatment based on vein and synthetic grafts provides sub-optimal benefits. We engineered a highly flexible and mechanically robust nanotextile-based vascular graft (NanoGraft) by interweaving nanofibrous threads of poly-L-lactic acid to address the unmet need. The NanoGrafts were rendered impervious with selective fibrin deposition in the micropores by pre-clotting. The pre-clotted NanoGrafts (4 mm diameter) and ePTFE were implanted in a porcine carotid artery replacement model. The fibrin-laden porous milieu facilitated rapid endothelization by the transmural angiogenesis in the NanoGraft. In-vivo patency of NanoGrafts was 100% at 2- and 4-weeks, with no changes over time in lumen size, flow velocities, and minimal foreign-body inflammatory reaction. However, the patency of ePTFE at 2-week was 66% and showed marked infiltration, neointimal thickening, and poor host tissue integration. The study demonstrates the in-vivo feasibility and safety of a thin-layered vascular prosthesis, viz., NanoGraft, and its potential superiority over the commercial ePTFE.

摘要

全球有数百万的患者因动脉粥样硬化而患有心肌梗塞或下肢坏疽/截肢。现有的基于静脉和合成移植物的手术治疗提供的效果并不理想。我们通过编织聚乳酸的纳米纤维线,开发出一种高度灵活且机械强度高的纳米纤维血管移植物(NanoGraft),以满足未满足的需求。通过预凝在微孔中选择性地沉积纤维蛋白,使 NanoGrafts 不透水。将预凝的 NanoGrafts(直径 4 毫米)和 ePTFE 植入猪颈动脉替代模型中。纤维蛋白填充的多孔环境促进了 NanoGraft 中壁内血管生成的快速内皮化。在 2 周和 4 周时,NanoGrafts 的通畅率为 100%,管腔大小、流速没有随时间变化,异物反应最小。然而,ePTFE 在 2 周时的通畅率为 66%,并显示出明显的浸润、新生内膜增厚和不良的宿主组织整合。该研究证明了薄层血管假体,即 NanoGraft 的体内可行性和安全性,及其相对于商业 ePTFE 的潜在优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd61/8822766/98c3ce926807/12951_2022_1268_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验